**Journal of Neonatal Surgery**
***ISSN(Online): 2226-0439***
***Vol. 14,Issue.31s (2025)***
*https://www.jneonatalsurg.com*

OPEN ACCESS

# Mechanistic Links Between Gut Microbiota And Depression: Pathways, Evidence, And Therapeutic Insights

**C. T. Nisha Rani[1] ,Dr. Charanjeet Singh[2]**

[1] PhD. Scholar, Sri Ganganagar Homoeopathic Medical College, Hospital and Research Institute, Tantia University, Sri Ganganagar, Rajasthan 335001, India

[2] Guide/ Supervisor, Principal -Sri Ganganagar Homoeopathic Medical College, Hospital and Research Institute, Tantia University, Sri Ganganagar, Rajasthan 335001, India

**Corresponding author:**

Dr Charanjeet Singh-

Guide/ Supervisor,Principal- Sri Ganganagar Homoeopathic Medical College, Hospital and Research Institute, Tantia University, Sri Ganganagar, Rajasthan 335001, India.

Email ID : principal.shmc@tantiauniversity.com

Cite this paper as C. T. Nisha Rani ,Dr. Charanjeet Singh (2025) Mechanistic Links Between Gut Microbiota And Depression: Pathways, Evidence, And Therapeutic Insights .Journal of Neonatal Surgery, 14.(31s) 1116-1122

**ABSTRACT**

Depression is a complex neuropsychiatric disorder with multifactorial origins involving genetic, environmental, and physiological factors. Emerging evidence highlights the gut microbiota as a critical regulator of brain function through its bidirectional communication with the central nervous system, termed the gut–brain axis. This review critically synthesizes current mechanistic insights linking gut microbial dysbiosis to depression through alterations in neurotransmitter metabolism, immune activation, systemic inflammation, tryptophan–kynurenine pathway modulation, and hypothalamic–pituitary–adrenal (HPA) axis dysregulation. Experimental and clinical studies indicate that microbiota-derived metabolites, including short-chain fatty acids and secondary bile acids, influence neuroendocrine signaling and behavioral outcomes. Furthermore, therapeutic strategies such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation show potential in restoring microbial homeostasis and alleviating depressive symptoms. Despite promising advances, inconsistencies across studies underscore the need for standardized methodologies, longitudinal monitoring, and mechanistic integration of multi-omic data. Collectively, these findings suggest that targeting the microbiota–gut–brain axis may open new avenues for precision psychiatry and the development of adjunctive therapies for depression..

**Keywords**: *gut microbiota; depression; gut–brain axis; neurotransmitters; inflammation; HPA axis; probiotics; psychobiotics; precision psychiatry*

## 1. INTRODUCTION

Depression and anxiety are highly prevalent mental health conditions that substantially impair daily functioning, quality of life, and socioeconomic productivity [1–5]. Epidemiological projections indicate that by 2030, depression may surpass cardiovascular disorders as the leading global illness [1]. Anxiety frequently co-occurs with depression, with nearly three-quarters of affected children and adolescents experiencing both disorders simultaneously [2]. Comorbidity is substantial, with 47–58% of individuals with depression developing anxiety, while approximately 56% of those with anxiety exhibit depressive symptoms [3]. Nearly half of all depressive episodes follow exposure to severe psychosocial stressors [4]. Globally, lifetime prevalence of anxiety and depression is estimated at 14% and 12%, respectively [5].

Beyond neurochemical imbalances, the gut microbiota—a complex community of ~100 trillion microorganisms—plays a pivotal role in mental health [6–8]. Under homeostasis, the microbiota maintains symbiosis with the host, predominantly through the phyla Firmicutes and Bacteroidetes, which comprise nearly 90% of the microbial population. Its composition is influenced by genetics, age, diet, environment, and stress exposure, affecting digestion, nutrient absorption, vitamin synthesis, and immune homeostasis [6–8]. Importantly, the gut communicates bidirectionally with the CNS through neural, endocrine, and immune pathways—the microbiota–gut–brain axis [6, 9, 10].

. Microbial dysbiosis can disrupt intestinal barrier integrity, increase systemic inflammation, and alter neurotransmitter synthesis, collectively influencing stress reactivity, mood regulation, and anxiety [9, 11, 12]. Chronic stress can also induce dysbiosis, promoting pro-inflammatory taxa and intestinal permeability (“leaky gut”), allowing microbial metabolites and

endotoxins to enter circulation and affect brain physiology [13, 14].
Although evidence links gut dysbiosis to neuropsychiatric disorders, causal mechanisms remain incompletely understood. Most studies are correlational, limited by small sample sizes, population heterogeneity, and inconsistent analytical methods. Future work integrating metagenomics, metabolomics, and neuroimaging is essential to clarify the molecular pathways of microbiota–brain interactions. This review critically examines recent advances in the gut–brain axis, highlighting mechanistic pathways, molecular mediators, and therapeutic potential.

**2. Composition and Diversity of the Human Gut Microbiota**

The human microbiome—defined as the collective genetic material and functional potential of microorganisms inhabiting the human body—is remarkably diverse, with only about one-third of microbial genes shared among healthy individuals [7]. Distinct microbial communities colonize ecological niches such as the gut, skin, oral cavity, lungs, and reproductive tract, each adapted to its environment [8].

The gut microbiota is the largest and most metabolically active microbial ecosystem, dynamically modulated by age, nutrition, hormonal fluctuations, and disease state. Perturbations exceeding adaptive capacity result in dysbiosis, characterized by loss of beneficial commensals, expansion of opportunistic species, and altered metabolite production. Dysbiosis contributes to metabolic, infectious, and neuropsychiatric disorders through immune activation and disrupted gut–brain communication [9, 11, 12].

Despite advances in metagenomic sequencing, inter-individual variability, non-standardized sampling, and short-term cross-sectional designs limit comparability. Longitudinal and functional approaches integrating microbial composition with metabolite and host-response data are essential to clarify the causal contribution of specific taxa to systemic and neurobehavioral health.

**3. Functional Roles of Gut Microbiota in Host Metabolism and Immunity**

*3.1 Metabolic Function: Fermentation into Short-Chain Fatty Acids (SCFAs)*

Gut microbes ferment dietary fibers into SCFAs (acetate, propionate, butyrate), which maintain intestinal homeostasis and influence glucose/lipid metabolism via G-protein–coupled receptors and histone deacetylase inhibition [9, 11, 15]. SCFAs also modulate neurotransmission, neuroinflammation, and microglial maturation, linking gut metabolism to CNS function. Translating preclinical findings to humans is challenging due to variability in microbiota composition and fiber intake.

*3.2 Protective Role: Colonization Resistance*

Commensal microbes prevent pathogenic invasion through nutrient competition, inhibitory metabolite production, and epithelial defense activation (e.g., antimicrobial peptides LL-37) [16, 17]. Dysbiosis weakens this resistance, increases pathogen susceptibility, and triggers systemic inflammation—a key pathway linking microbiota to depression.

*3.3 Immune Modulation*

Butyrate promotes regulatory T-cell differentiation, enhances barrier integrity, and attenuates NF-κB-mediated cytokine production (e.g., TNF-α, IL-6) [15, 18, 19]. Impaired SCFA production is associated with low-grade systemic inflammation observed in depression. Human studies remain largely correlative, highlighting the need for integrative microbial-immune-metabolomic analyses.

Despite substantial preclinical evidence elucidating the metabolic, protective, and immunomodulatory roles of gut microbiota, important research gaps remain in humans. The translation of SCFA-mediated effects on neurotransmission, neuroinflammation, and microglial maturation is limited by inter-individual variability in microbiota composition, dietary fiber intake, and metabolite bioavailability. Similarly, the mechanisms underlying colonization resistance and its contribution to systemic inflammation in depressive disorders are not well defined in clinical populations. Although impaired SCFA production has been associated with low-grade inflammation, causal links remain largely correlative, underscoring the need for integrative studies that combine microbial sequencing, metabolomics, and immune profiling. Standardized longitudinal investigations are therefore essential to clarify how specific microbial taxa and metabolites modulate metabolic and immune pathways relevant to depression.

*4. The Gut–Brain Axis in Depression: Mechanistic Pathways and Evidence*

The gut–brain axis represents a complex, bidirectional communication network linking the gastrointestinal tract and the central nervous system (CNS) via neural, endocrine, immune, and metabolic pathways [20]. Current evidence indicates that microbial dysbiosis can perturb these pathways, influencing brain function through multiple mechanisms, including modulation of neurotransmitters, short-chain fatty acids (SCFAs), secondary bile acids, and tryptophan-derived metabolites [9, 21–23]. While preclinical studies robustly demonstrate that alterations in these microbial products can affect mood and behavior, human evidence remains largely correlative, with inconsistent replication across populations and methodological heterogeneity.

Neuroimmune interactions are a critical conduit through which gut microbes affect the CNS. Dysbiosis enhances systemic

inflammation and compromises blood–brain barrier (BBB) integrity, facilitating entry of inflammatory mediators and microbial metabolites into the brain, thereby promoting neuroinflammation and neuronal dysfunction [10, 24–27]. Experimental models indicate that disrupted tight-junction proteins (e.g., occludin, claudin) mediate BBB permeability, yet translation to human pathology is limited, highlighting a need for longitudinal studies integrating neuroimaging and immune profiling to confirm these mechanisms in clinical populations.

Altered tryptophan metabolism further links microbial activity to depression. Under inflammatory conditions, tryptophan is preferentially shunted toward the kynurenine pathway, resulting in accumulation of neurotoxic metabolites such as quinolinic acid, which contribute to excitotoxicity, oxidative stress, and synaptic dysfunction [28, 29]. Although animal studies elucidate these pathways, quantitative human data connecting specific microbial taxa to kynurenine flux and downstream neurobehavioral outcomes remain scarce.

SCFAs and bile acids are additional key mediators of gut–brain communication, influencing gene expression, neurotransmitter release, and vagal signaling [30, 31]. Preclinical evidence suggests SCFAs modulate microglial maturation and anti-inflammatory pathways, while bile acids engage farnesoid X receptor and TGR5 signaling to affect stress reactivity. However, human studies are limited by variability in dietary fiber intake, microbial composition, and metabolite bioavailability, necessitating standardized metabolomic and interventional approaches.

Finally, the HPA axis demonstrates a reciprocal relationship with the microbiota, where dysbiosis exacerbates stress-induced cortisol dysregulation, and microbial restoration can normalize exaggerated stress responses observed in germ-free animals [13, 32, 33]. While these findings offer compelling mechanistic insights, robust clinical validation is lacking, particularly regarding strain-specific effects and long-term modulation of HPA activity in humans.

Despite these advances, several research gaps remain that limit translation to clinical practice. Longitudinal human studies integrating microbiome profiling, metabolomic analyses, and neuroimaging are needed to establish causal links between microbial alterations and depressive outcomes. Quantitative assessments of microbial contributions to tryptophan–kynurenine metabolism and their neurobehavioral consequences are largely missing. Standardized measurement of SCFA and bile-acid signaling across diverse populations is required to clarify their roles in mood regulation. Additionally, strain-specific effects of the microbiota on HPA axis function and their clinical relevance remain poorly understood, emphasizing the need for targeted mechanistic investigations to bridge preclinical findings with therapeutic applications.

**5. Microbial Modulation of Neurotransmission, Immunity, and Endocrine Function**

*5.1 Neurotransmitter Modulation*

Bacterial taxa produce or regulate serotonin, dopamine, GABA, and acetylcholine [34]. Dysbiosis impairs neurotransmitter availability and serotonergic/GABAergic signaling, key pathways in depression [35]. Probiotic supplementation restores GABAergic tone in preclinical models; human studies are inconsistent, highlighting strain-specific and population-dependent effects.

*5.2 Immune System Activation*

“Leaky gut” enables translocation of LPS, inducing chronic inflammation (IL-1β, IL-6, TNF-α) that promotes neuroinflammation and alters monoaminergic signaling [12, 36]. Integrative studies are required to determine whether inflammation is a mediator or consequence of dysbiosis.

*5.3 Tryptophan–Kynurenine Pathway*

Cytokine-mediated upregulation of indoleamine 2,3-dioxygenase shifts tryptophan metabolism toward kynurenine, producing neuroactive metabolites that induce synaptic dysfunction and oxidative stress [28, 29]. Microbial influence on this pathway requires human metabolomic-microbiomic validation.

*5.4 Metabolite Signaling*

SCFAs and secondary metabolites modulate gene expression, barrier integrity, and neuroprotection [30, 31]. Animal studies support these effects; human mechanistic data are limited.

*5.5 HPA Axis Regulation*

Dysbiosis and stress reciprocally regulate cortisol secretion [13, 32, 33]. Microbial restoration may attenuate HPA hyperactivity and stress-related psychopathology. Human interventional evidence is limited.

Despite compelling preclinical evidence linking gut microbes to neurotransmission, immune modulation, tryptophan metabolism, metabolite signaling, and HPA axis regulation, significant research gaps remain in human studies. The strain-specific and population-dependent effects of probiotics on neurotransmitter systems require rigorous, standardized investigation. The causal role of inflammation in mediating dysbiosis-induced neurobehavioral changes remains unclear, necessitating integrative studies combining cytokine profiling, microbial sequencing, and behavioral assessments. Quantitative validation of microbial contributions to the tryptophan–kynurenine pathway and downstream neuroactive

metabolites in humans is largely lacking. Similarly, while SCFAs and secondary metabolites demonstrate neuroprotective and gene-regulatory effects in animal models, mechanistic confirmation in clinical populations is limited. Finally, the reciprocal regulation of the HPA axis by stress and microbiota, though promising in preclinical studies, demands longitudinal human intervention trials to clarify strain-specific effects, treatment duration, and sustained modulation of cortisol dynamics. Addressing these gaps is essential to translate mechanistic insights into effective microbiota-targeted therapies for depression.

**6. Preclinical and Clinical Evidence Linking Gut Microbiota to Depression**

Preclinical studies provide robust evidence supporting a causal role of gut microbiota in depression-like phenotypes. Germ-free or antibiotic-treated rodents exhibit exaggerated hypothalamic–pituitary–adrenal (HPA) axis responses, altered monoamine metabolism, and behavioral anhedonia, which can be reversed by colonization with specific microbial strains or fecal microbiota transplantation (FMT) from healthy donors [14, 37]. These findings highlight that microbial composition and metabolite signaling directly influence neuroendocrine function, stress reactivity, and synaptic plasticity. In humans, observational studies consistently report a reduction in short-chain fatty acid (SCFA)-producing taxa such as Faecalibacterium and Coprococcus, alongside an increase in potentially pathogenic genera including Alistipes and Enterobacteriaceae in patients with major depressive disorder [38]. While these correlations support the translational relevance of preclinical findings, they remain limited by heterogeneity in diet, medication use, and sequencing methodologies, making causal inference challenging.

Intervention trials targeting the microbiota—through probiotics, prebiotics, dietary modification, or FMT—have demonstrated modest improvements in mood and stress biomarkers [39–42]. For example, probiotic supplementation with Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 has been associated with reduced psychological distress and cortisol levels, while prebiotics such as galacto-oligosaccharides (GOS) can lower anxiety scores and attenuate cortisol awakening responses. Mediterranean-style dietary interventions, which enhance microbial diversity and SCFA production, have also shown favorable effects on depressive symptoms [41]. Nevertheless, results are inconsistent due to small sample sizes, variability in intervention composition, and short study durations, limiting generalizability and reproducibility across populations. Early FMT studies suggest potential benefits in modulating mood and microbial profiles, but safety concerns, donor variability, and long-term ecological stability restrict clinical application.

Despite these promising findings, significant research gaps remain. There is a pressing need for longitudinal human studies that integrate multi-omic approaches—combining metagenomics, metabolomics, immune profiling, and neuroimaging—to clarify causal mechanisms. Furthermore, standardized microbial interventions specifying strain, dosage, and duration are essential to improve reproducibility and identify effective therapeutic regimens. Finally, mechanistic studies investigating the specific roles of microbial taxa and metabolites on central nervous system pathways in humans are critically needed to translate preclinical insights into precision psychiatry interventions. Addressing these gaps will be pivotal for advancing microbiota-targeted therapies as a scientifically grounded adjunct in depression management.

**7. Therapeutic Implications of Microbiota-Targeted Interventions**

Microbiota-targeted interventions have emerged as promising adjunctive strategies for managing depressive disorders, yet their efficacy remains variable and context-dependent. Probiotics and psychobiotics, particularly strains such as Lactobacillus helveticus R0052 and Bifidobacterium longum R0175, have been shown to improve mood, reduce psychological distress, and modulate HPA axis activity in both preclinical models and small human trials [35, 41]. However, these effects are often strain-specific, short-term, and inconsistent across studies, highlighting the need for rigorous, standardized trials to determine optimal formulations and dosing regimens. Prebiotics, such as galacto-oligosaccharides (GOS), selectively stimulate beneficial microbial taxa and indirectly influence neuroendocrine signaling. Yet, their efficacy is influenced by an individual's baseline microbiota composition, suggesting that personalized approaches may be required to maximize therapeutic benefit [38].

Dietary interventions, most notably adherence to Mediterranean-style diets rich in fiber, polyphenols, and omega-3 fatty acids, have demonstrated improvements in depressive outcomes by enhancing microbial diversity and promoting SCFA production [42]. Despite these encouraging results, methodological limitations—including reliance on self-reported dietary intake, variable adherence, and short-term follow-up—limit the generalizability and robustness of findings. Fecal microbiota transplantation (FMT) represents a more direct approach to modifying gut microbial composition. Preclinical studies and early pilot trials indicate potential benefits in mood regulation; however, donor variability, safety concerns, and the long-term stability of transferred microbiota currently constrain widespread clinical application [37].

Critical research gaps remain in translating these interventions into precision psychiatry. There is a need for strain-specific, evidence-based microbial therapies with clearly defined dosages and treatment durations. Integrating multi-omic endpoints—including microbiome, metabolome, immune, and neuroendocrine markers—will be essential to elucidate mechanistic pathways and identify biomarkers of response. Moreover, the long-term ecological effects and sustainability of interventions, particularly FMT, require systematic investigation [43]. Finally, personalized interventions tailored to an individual's

baseline microbial composition may enhance efficacy, minimize variability, and support the development of microbiota-directed precision therapies for depression.

## 8. Conclusion and Future Perspectives

The gut microbiota has emerged as a central mediator of depression, influencing key neurobiological processes including neurotransmission, immune signaling, metabolite production, and HPA axis regulation [25–35]. Preclinical studies provide strong mechanistic evidence, demonstrating causal relationships between microbial dysbiosis and depressive-like behaviors, altered stress responses, and neurochemical changes [14, 37]. Human studies largely support these associations, revealing reduced SCFA-producing taxa and increased potential pathogens in major depressive disorder [38–41]; however, findings remain heterogeneous due to small sample sizes, population variability, and methodological inconsistencies. Collectively, these data underscore the critical role of the microbiota–gut–brain axis while highlighting the limitations of current evidence and the need for more rigorous investigation.

Microbiota-targeted interventions—including probiotics, prebiotics, dietary modulation, and fecal microbiota transplantation—show encouraging potential for improving depressive outcomes [35, 37, 41, 42]. Nonetheless, translation into clinical practice is constrained by variability in microbial strains, dosage, duration, and long-term ecological effects. Standardization of interventions, integration of multi-omic endpoints, and longitudinal follow-up are essential to establish reproducible efficacy and elucidate underlying mechanisms. Personalized strategies that consider baseline microbial composition may further optimize therapeutic outcomes and reduce inter-individual variability.

Future research should prioritize large-scale, longitudinal multi-omic studies to clarify causal links between specific microbial taxa, metabolites, and CNS pathways. The development of strain-specific, personalized microbial interventions will be critical for advancing precision psychiatry. Interdisciplinary collaboration among microbiologists, neuroscientists, psychiatrists, and computational biologists will facilitate the translation of preclinical mechanistic insights into robust clinical applications. Additionally, exploration of novel microbial pathways in humans through metabolomics and neuroimaging will likely reveal previously unrecognized mechanisms underlying depression. Addressing these gaps may allow microbiota modulation to evolve from an experimental adjunct to a core component of precision psychiatry, enabling targeted prevention and treatment of depression.

## 9. Author Contributions (CRediT roles)

C. T. Nisha Rani: Conceptualization, Methodology, Investigation, Writing – Original Draft.

Charanjeet Singh: Supervision, Validation, Writing – Review & Editing.

## 10. Declaration of AI Use

*Declaration of Generative AI and AI-assisted technologies in the writing process*

During the preparation of this work the author(s) used ChatGPT (OpenAI) in order to assist with language editing and improving clarity. After using this tool, the author(s) reviewed and edited the content as needed and take full responsibility for the content of the publication.

## 11. Acknowledgments

The authors sincerely thank Sri Ganganagar Homoeopathic Medical College, Tantia University, for institutional support during the preparation of this manuscript. We also gratefully acknowledge Dr. S. Jeeva, Former Head and Assistant Professor, Department of Microbiology, Udaya College of Arts and Science, for her valuable guidance, constructive suggestions, and encouragement throughout the course of this work.

## REFERENCES

1. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 2007;370(9590):841-50.

2. Angola A, Costello EJ. Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues. Am J Psychiatry. 1993;150(12):1779-91.

3. Wittchen HU, Kessler RC, Pfister H, Höfler M, Lieb R. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000;406:14-23.

4. Beaglehole B, Mulder RT, Frampton CM, Boden JM, Newton-Howes G, Bell CJ. Psychological distress and psychiatric disorder after natural disasters: systematic review and meta-analysis. Br J Psychiatry. 2018;213(6):716-22.

5. Johannsen M, Nissen ER, Lundorff M, O'Toole MS. Mediators of acceptance and mindfulness-based therapies for anxiety and depression: a systematic review and meta-analysis. Clin Psychol Rev. 2022;94:102156.

6. Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics. 2018;15(1):36-59.

7. Mueller NT, Bakacs E, Combellick J, Grigoryan Z, Dominguez-Bello MG. The infant microbiome development: mom matters. Trends Mol Med. 2015;21(2):109-17.

8. Ahrodia T, Das S, Bakshi S, Das B. Structure, functions, and diversity of the healthy human microbiome. Prog Mol Biol Transl Sci. 2022;191:53-82. doi:10.1016/bs.pmbts.2022.07.003

9. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25.

10. Rutsch A, Kantsjö JB, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol. 2020;11:3237.

11. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-45. doi:10.1016/j.cell.2016.05.041

12. Maes M, Kubera M, Leunis JC. The gut–brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS. Neuro Endocrinol Lett. 2008;29(1):117-24.

13. Moloney RD, Desbonnet L, Clarke G, Dinan TG, Cryan JF. The microbiome: stress, health and disease. Mamm Genome. 2014;25(1-2):49-65.

14. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, et al. The microbiome–gut–brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666-73.

15. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247-52. doi:10.1073/pnas.1322269111

16. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29-41. doi:10.1111/1462-2920.13589

17. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006;103(24):9178-83. doi:10.1073/pnas.0602888103

18. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-50. doi:10.1038/nature12721

19. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619-25. doi:10.3945/jn.109.104638

20. Alli SR, Gorbovskaya I, Liu JCW, Kolla NJ, Brown L, Müller DJ. The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: a systematic review of clinical trials and observational studies. Int J Mol Sci. 2022;23(8):4494.

21. Shishov VA, Kirovskaya TA, Kudrin VS, Oleskin AV. Amine neuromediators, their precursors, and oxidation products in the culture of Escherichia coli K-12. Appl Biochem Microbiol. 2009;45(5):494-7.

22. Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113(2):411-7.

23. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-76.

24. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158.

25. Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, et al. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013;35(1):179-98.

26. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med. 2003;9(7):900-6.

27. Kumar A, Pramanik J, Goyal N, Chauhan D, Sivamaruthi BS, Prajapati BG, et al. Gut microbiota in anxiety and depression: unveiling the relationships and management options. Pharmaceuticals (Basel). 2023;16(4):565. doi:10.3390/ph16040565

28. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128-33.

29. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74(10):720-6.

30. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.

31. Schwarcz R, Stone TW. The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology. 2017;112(Pt B):237-47.

32. Savitz J. Role of kynurenine metabolism pathway activation in major depressive disorders. Curr Top Behav Neurosci. 2017;31:249-67.

33. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461-78.

34. Chen S, Luo J, Li M, He H, Zheng P, Jiang H, et al. Altered bile acid metabolism in depression: mechanisms and therapeutic relevance. Front Pharmacol. 2021;12:646845.

35. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, et al. Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263-75.

36. Foster JA, Rinaman L, Cryan JF. Stress & the gut–brain axis: regulation by the microbiome. Neurobiol Stress. 2017;7:124-36.

37. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry. 2016;21(6):786-96.

38. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623-32.

39. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2(4):256-61.

40. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PWJ. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl). 2015;232(10):1793-801.

41. Jacka FN, O'Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Med. 2017;15:23.

42. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701-12.

43. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2021;20(1):22..

.